Drugs Made In America Acquisition Corp.

Status: Pre-Deal
U=S+R R=S/8
IPO Proceeds, $M $200.00M
IPO Date Jan 28, 2025
CEO Lynn Stockwell
Left Lead Clear Street
IPO Cash in Trust 100.5%
SPAC Tenor 15+(2*3)
IPO Sector Healthcare

Pharmaceutical industry

IPO Geography Global
Target Company TBD
Deal Announced TBD
Deal Size, $M TBD
Deal Sector TBD
Deal Geography TBD
SEC Filings www.sec.gov
Approval Vote TBD
Amendment Vote TBD
DMAA DMAAU DMAAR

Sign up for Free Trial

No credit card required

Sign in for more on Drugs Made In America Acquisition Corp.:

  • Structure and cap table
  • 5 directors & officers
  • 6 filings and events
  • 1 underwriters
Structure

Sign in to view structure, cap table, and calendar of events.

Team
Name Age Title
Lynn Stockwell 68 Chief Executive Officer and Executive Chair of the Board
Glenn Worman 65 Chief Financial Officer
Catherine Do 45 Director
G. Sridhar Prasad 61 Director
Myron W. Shulgan 78 Director

Sign in to view team biographies and more sponsor and affiliate data.

Advisors
Underwriters
Clear Street BR 20,000,000 units
20,000,000 units
Up-Front UW fee 0.50 %
Deferred UW fee
3.00 %

Sign in to view more advisor data.

Filings
Aug 1, 2024 Initial S-1
Sep 27, 2024

Sign In to view filing content.

Nov 7, 2024

Sign In to view filing content.

Jan 14, 2025

Sign In to view filing content.

Jan 27, 2025

Sign In to view filing content.

Jan 29, 2025 424B4 IPO Prospectus
Shareholders

Sign in to view shareholders 13F filing data.